211 related articles for article (PubMed ID: 37723306)
21. TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Josefsson SE; Beiske K; Blaker YN; Førsund MS; Holte H; Østenstad B; Kimby E; Köksal H; Wälchli S; Bai B; Smeland EB; Levy R; Kolstad A; Huse K; Myklebust JH
Cancer Immunol Res; 2019 Mar; 7(3):355-362. PubMed ID: 30659053
[TBL] [Abstract][Full Text] [Related]
22. Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice.
Li Y; Wu B; Hossain MJ; Quagliata L; O'Meara C; Wilkins MR; Corley S; Khachigian LM
J Transl Med; 2023 Jul; 21(1):467. PubMed ID: 37452307
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness.
Lau E; Kwong G; Fowler TW; Sun BC; Donohoue PD; Davis RT; Bryan M; McCawley S; Clarke SC; Williams C; Banh L; Irby M; Edwards L; Storlie M; Kohrs B; Lilley GWJ; Smith SC; Gradia S; Fuller CK; Skoble J; Garner E; van Overbeek M; Kanner SB
Cytotherapy; 2023 Jul; 25(7):750-762. PubMed ID: 37086241
[TBL] [Abstract][Full Text] [Related]
24. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells.
Moussaieff A; Rouleau M; Kitsberg D; Cohen M; Levy G; Barasch D; Nemirovski A; Shen-Orr S; Laevsky I; Amit M; Bomze D; Elena-Herrmann B; Scherf T; Nissim-Rafinia M; Kempa S; Itskovitz-Eldor J; Meshorer E; Aberdam D; Nahmias Y
Cell Metab; 2015 Mar; 21(3):392-402. PubMed ID: 25738455
[TBL] [Abstract][Full Text] [Related]
25. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
Tiemann M; Samoilova V; Atiakshin D; Buchwalow I
BMC Res Notes; 2020 Mar; 13(1):139. PubMed ID: 32143684
[TBL] [Abstract][Full Text] [Related]
26. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
27. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
Green MR; Rodig S; Juszczynski P; Ouyang J; Sinha P; O'Donnell E; Neuberg D; Shipp MA
Clin Cancer Res; 2012 Mar; 18(6):1611-8. PubMed ID: 22271878
[TBL] [Abstract][Full Text] [Related]
28. ATP-citrate lyase links cellular metabolism to histone acetylation.
Wellen KE; Hatzivassiliou G; Sachdeva UM; Bui TV; Cross JR; Thompson CB
Science; 2009 May; 324(5930):1076-80. PubMed ID: 19461003
[TBL] [Abstract][Full Text] [Related]
29. Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic-Epigenetic Cross-Talk.
Greenwood DL; Ramsey HE; Nguyen PTT; Patterson AR; Voss K; Bader JE; Sugiura A; Bacigalupa ZA; Schaefer S; Ye X; Dahunsi DO; Madden MZ; Wellen KE; Savona MR; Ferrell PB; Rathmell JC
Immunohorizons; 2022 Dec; 6(12):837-850. PubMed ID: 36547387
[TBL] [Abstract][Full Text] [Related]
30. Toll-like Receptor Signaling Rewires Macrophage Metabolism and Promotes Histone Acetylation via ATP-Citrate Lyase.
Lauterbach MA; Hanke JE; Serefidou M; Mangan MSJ; Kolbe CC; Hess T; Rothe M; Kaiser R; Hoss F; Gehlen J; Engels G; Kreutzenbeck M; Schmidt SV; Christ A; Imhof A; Hiller K; Latz E
Immunity; 2019 Dec; 51(6):997-1011.e7. PubMed ID: 31851905
[TBL] [Abstract][Full Text] [Related]
31. FABP7 Regulates Acetyl-CoA Metabolism Through the Interaction with ACLY in the Nucleus of Astrocytes.
Kagawa Y; Umaru BA; Shima H; Ito R; Zama R; Islam A; Kanno SI; Yasui A; Sato S; Jozaki K; Shil SK; Miyazaki H; Kobayashi S; Yamamoto Y; Kogo H; Shimamoto-Mitsuyama C; Sugawara A; Sugino N; Kanamori M; Tominaga T; Yoshikawa T; Fukunaga K; Igarashi K; Owada Y
Mol Neurobiol; 2020 Dec; 57(12):4891-4910. PubMed ID: 32812201
[TBL] [Abstract][Full Text] [Related]
32. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S; Koyama S; Itahashi K; Tanegashima T; Lin YT; Togashi Y; Kamada T; Irie T; Okumura G; Kono H; Ito D; Fujii R; Watanabe S; Sai A; Fukuoka S; Sugiyama E; Watanabe G; Owari T; Nishinakamura H; Sugiyama D; Maeda Y; Kawazoe A; Yukami H; Chida K; Ohara Y; Yoshida T; Shinno Y; Takeyasu Y; Shirasawa M; Nakama K; Aokage K; Suzuki J; Ishii G; Kuwata T; Sakamoto N; Kawazu M; Ueno T; Mori T; Yamazaki N; Tsuboi M; Yatabe Y; Kinoshita T; Doi T; Shitara K; Mano H; Nishikawa H
Cancer Cell; 2022 Feb; 40(2):201-218.e9. PubMed ID: 35090594
[TBL] [Abstract][Full Text] [Related]
33. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
Xerri L; Chetaille B; Serriari N; Attias C; Guillaume Y; Arnoulet C; Olive D
Hum Pathol; 2008 Jul; 39(7):1050-8. PubMed ID: 18479731
[TBL] [Abstract][Full Text] [Related]
34. Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma.
Zuo M; Shen H; Yin J; Wang W; Zhang Y; Zhou DB; Zhang W
Leuk Res; 2018 Jul; 70():56-61. PubMed ID: 29859415
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
36. Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells.
Liu MY; Klement JD; Langan CJ; van Riggelen J; Liu K
Cell Immunol; 2021 Aug; 366():104397. PubMed ID: 34157461
[TBL] [Abstract][Full Text] [Related]
37. Expression of Programmed Cell Death-1 and Programmed Cell Death Ligands in Nodal Peripheral T-Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Asawapanumas T; Tangnantachai N; Sukswai N; Assanasen T; Chanswangphuwana C; Lawsut P; Polprasert C; Rojnuckarin P; Bunworasate U; Wudhikarn K
Acta Haematol; 2022; 145(5):542-552. PubMed ID: 35235931
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-10 receptor signaling promotes the maintenance of a PD-1
Hanna BS; Llaó-Cid L; Iskar M; Roessner PM; Klett LC; Wong JKL; Paul Y; Ioannou N; Öztürk S; Mack N; Kalter V; Colomer D; Campo E; Bloehdorn J; Stilgenbauer S; Dietrich S; Schmidt M; Gabriel R; Rippe K; Feuerer M; Ramsay AG; Lichter P; Zapatka M; Seiffert M
Immunity; 2021 Dec; 54(12):2825-2841.e10. PubMed ID: 34879221
[TBL] [Abstract][Full Text] [Related]
39. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
40.
Jung KH; Lee JH; Kim M; Cho YS; Lee KH
Mol Imaging; 2022; 2022():5916692. PubMed ID: 35250391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
